Invitation to Participate: SWEET-PLUS Study

You are invited to take part in a research study called SWEET-PLUS (NIHR Research for Patient Benefit: 207952), run by Newcastle and Oxford Brookes Universities. SWEET-PLUS aims to understand experiences of, and factors influencing adherence to, CDK4/6 inhibitors (abemaciclib, ribociclib) among women with ER+ve early breast cancer. We would like to speak with healthcare professionals from a variety of specialisms who encounter patients with ER+ve early breast cancer who have been prescribed CDK4/6 inhibitors (e.g. oncologists, breast surgeons, specialist pharmacists, cancer specialist nurses, etc.). By participating in a one-hour online focus group or interview (whichever you prefer), you can help us understand what support these patients currently receive, and what additional help may be needed.

Please email [email protected] or leave your contact details in the form and a member of the team will be in touch with more details: https://app.onlinesurveys.jisc.ac.uk/s/newcastle/sweet-plus-study-hcp

SWEET-PLUS study Recruitment Flyer

Latest News

By UK SACT Protocols Pilot Team on 20th November 2026

Have Your Say: Review the First UK SACT Protocol and Provide Feedback

Dear Colleagues working in cancer services We are writing to invite you to review and provide feedback on the first protocol produced as part of the UK SACT Protocols Pilot.…

Read article
By Mohammed Patel on 11th November 2026

UK BMT Pharmacists Group Educational Meeting – Friday 13th November 2026. Time:14:00 to 16:00

The next UK BMT Pharmacists Group Educational Meeting is on Friday 13th November, 2pm–4pm. The sessions include: Maintenance Therapy for AML After Allogeneic BMT with Dr Mili Shah, Consultant Haematologist,…

Read article
By UK SACT Board on 9th November 2026

New UK SACT Board National Intrathecal and Intraventricular SACT Guidance

Dear colleagues, We are pleased to share the newly published UK SACT Board National Guidance on the Safe Administration of Systemic Anti-Cancer Therapies via the Intrathecal or Intraventricular Routes. This…

Read article
By BOPA Executive Committee on 9th November 2026

BOPA members flying the flag for cancer pharmacy at ESMO 2026

It was fantastic to see BOPA members representing cancer pharmacy at ESMO Congress 2026 in Madrid, which brought together the global cancer community from 23 to 27 October to share…

Read article